AbbVie Inc.
285.64USD
+0.4500 (+0.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ABBV.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Price
Reading the stored fundamentals…
Dated 52-week rows are the highest and lowest CLOSE and the day each happened, which sits a little inside the intraday range a vendor quotes. Quotes are refreshed once a night — during a session the price above is the previous close.
Is the price low against peers, cash flow and analyst targets?
Do analysts expect earnings and revenue to keep growing?
1 of 6 checks could not be assessed (there is no analyst coverage stored).
Has the business grown and earned good returns on its filed numbers?
1 of 6 checks could not be assessed (the figures they need are not meaningful here).
Can the balance sheet carry its debt?
1 of 6 checks could not be assessed (the stored data lacks the figures they need).
Is the dividend decent, covered and steady?
Each axis asks six plain questions of the stored data. A check that passes counts one. A check the stored data cannot answer is left out of the count, never counted as a fail, and an axis needs four answerable checks to show a result. Axes are never added together: there is no overall score. The thresholds are conventional rules of thumb and are blunt across sectors, so each check is listed with its rule and the figure it used.
P/E below peers
Trailing P/E is positive and below the median of its peers: the companies in its industry if there are at least 5, else its sector if at least 10, else the whole market if at least 30, always in the same currency.
P/E 80.7 against a peer median of 39.0 (9 USD companies in Drug Manufacturers - General).
Did not pass
PEG ratio
The PEG ratio is positive and at most 1.5.
PEG 0.58.
Passed
EV/EBITDA below peers
EV/EBITDA is positive and below the peer median, with peers chosen as for P/E. Not applied to financial companies.
EV/EBITDA 18.5 against a peer median of 14.1 (10 USD companies in Drug Manufacturers - General).
Did not pass
Price/book below peers
Price to book is positive and below the peer median, with peers chosen as for P/E.
Book value is negative (liabilities exceed assets), so there is no price/book to compare.
Did not pass
Statements: SEC filings, newest period 06/2026.
Peers: P/E against 9 USD companies in Drug Manufacturers - General; EV/EBITDA against 10 USD companies in Drug Manufacturers - General; price/book against 10 USD companies in Drug Manufacturers - General.
Rules of thumb applied to stored filings and quote data. Statements are as of the newest period shown above; multiples, analyst targets, estimates and yield come from a best-effort refresh and can lag by days. A count of plain checks, not a rating, a valuation or investment advice. Terms
Free cash flow yield
Free cash flow is at least 4.5% of market cap, the risk-free rate used across this site. Not applied to financial companies.
Free cash flow yield 3.6% against a 4.5% risk-free rate.
Did not pass
Analyst target above price
The mean analyst target is at least 15% above the last close, from at least 3 analysts. A published consensus, not a fair value.
Mean analyst target below the last close by 0.2% (27 analysts).
Did not pass
Earnings growth, next year
Consensus EPS for next fiscal year is at least 10% above this year's consensus, from at least 3 analysts.
Next year's EPS: consensus up 16.1% (25 analysts).
Passed
Earnings growth, this year
Consensus EPS for this fiscal year is at least 10% above last year's figure on the same street basis, from at least 3 analysts.
This year's EPS: consensus up 39.6% (27 analysts).
Passed
Revenue growth, next year
Consensus revenue for next fiscal year is at least 5% above this year's consensus, from at least 3 analysts.
Next year's revenue: consensus up 8.8% (22 analysts).
Passed
Revenue growth, this year
Consensus revenue for this fiscal year is at least 5% above last year's reported revenue, from at least 3 analysts.
This year's revenue: consensus up 10.6% (24 analysts).
Passed
Estimates rising
More analysts raised than cut this year's EPS estimate over the last 90 days, with at least 2 revisions in all.
No analyst estimates are stored for this security.
Not assessed
Revenue growth, latest quarter
Revenue in the latest quarter is at least 8% above the same quarter a year earlier.
Latest-quarter revenue up 10.2% on a year earlier.
Passed
Earnings growth, multi-year
Net income grew at least 5% a year over up to 5 fiscal years (at least 3 annual figures, positive at both ends).
Net income fell 1.7% a year, FY2020 to FY2025.
Did not pass
Earnings growth, last year
Net income over the latest twelve months is above the twelve months before it, and positive.
Net income up 67.7% (twelve months to 06/2026).
Passed
Revenue growth, multi-year
Revenue grew at least 3% a year over up to 5 fiscal years (at least 3 annual figures).
Revenue grew 6.0% a year, FY2020 to FY2025.
Passed
Return on equity
Return on equity is at least 15%: twelve-month net income over average equity. Not meaningful when equity is negative.
Return on equity is not meaningful: equity is not positive.
Not assessed
Return on assets
Return on assets is at least 5%: twelve-month net income over average assets. Not applied to financial companies.
Return on assets 4.6%: twelve-month net income over the average assets.
Did not pass
Cash earnings
Operating cash flow over the latest twelve months is positive and at least net income. Not applied to financial companies.
Operating cash flow was at or above net income over the last twelve months.
Passed
Current ratio
Current assets are at least 1.0x current liabilities. Not applied to financial companies.
Current ratio 0.8x.
Did not pass
Short-term assets cover long-term liabilities
Current assets are at least the liabilities that fall due after a year (total liabilities less current liabilities). Not applied to financial companies.
The newest stored balance sheet lacks the figures this needs.
Not assessed
Debt to equity
Total debt is at most 100% of equity; no debt passes, negative equity with debt does not. Not applied to financial companies.
Equity is negative while the company carries debt.
Did not pass
Net debt to EBITDA
Net debt (total debt less cash) is at most 3.0x EBITDA; a net cash position passes. Not applied to financial companies.
Net debt is 3.6x EBITDA.
Did not pass
Interest cover
Operating income covers interest expense at least 3.0x; no debt passes. Not applied to financial companies.
Operating income covers interest 5.8x.
Passed
Cash flow to debt
Operating cash flow is at least 20% of total debt; no debt passes. Not applied to financial companies.
Operating cash flow is 27.5% of total debt.
Passed
Dividend yield
The dividend yield is at least 2%.
Dividend yield 2.42%.
Passed
Payout ratio
Dividends paid are at most 75% of net income. Not applied to real estate companies, whose net income is after depreciation.
Dividends paid were 190% of net income.
Did not pass
Free cash flow cover
Free cash flow covers the dividends paid at least 1.0x. Not applied to financial companies.
Free cash flow covers dividends 1.5x.
Passed
Paid every year
A dividend was paid in every one of the last 4 to 8 fiscal years stored (consecutive years, all present). A year missing from the filings data is not read as no dividend, so a gap makes this not assessed.
A dividend was paid in all 8 fiscal years, FY2018 to FY2025.
Passed
No cuts
Total dividends paid never fell by more than 20% from one fiscal year to the next in that window.
No fall of more than 20% between fiscal years, FY2018 to FY2025.
Passed
Growing dividend
Total dividends paid grew at least 3% a year across that window. The total, not per share: no per-share dividend history is stored.
Total dividends grew 11.1% a year, FY2018 to FY2025.
Passed